SCHEMBL1237498

SCHEMBL1237498

Cc1cccc(C(=O)Nc2ccc3c(c2)nc(NC2CCN(C)CC2)n3Cc2nc(C)ccc2O)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 3/20 0.49
NPC1 O15118 2/20 0.49
LMNA P02545 2/20 0.47
TP53 P04637 2/20 0.47
INSR P06213 2/20 0.43
ITK Q08881 1/20 0.43
MAPT P10636 2/20 0.41
LCK P06239 2/20 0.41
LYN P07948 1/20 0.41
SRC P12931 1/20 0.41
KDR P35968 1/20 0.41
STAT3 P40763 1/20 0.41
SMN1; SMN2 Q16637 1/20 0.41
HTR1A P08908 1/20 0.41
HTR1D P28221 1/20 0.41
HTR1B P28222 1/20 0.41
HTR1F P30939 1/20 0.41
MAPK14 Q16539 1/20 0.40
XDH P47989 1/20 0.40
THRB P10828 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1238612 0.94 NPC1 (0.43) RAB9ANPC1LMNATP53INSR
SCHEMBL1237482 0.89 ACSS2 (0.41) RAB9ANPC1TP53INSRMAPT
SCHEMBL8294930 0.80 KCNH2 (0.41) LMNATP53MAPTLCKSMN1; SMN2
SCHEMBL1238600 0.78 SCD (0.40) MAPT
SCHEMBL8293602 0.78 KMT2A (0.43) RAB9ALMNAMAPTSMN1; SMN2
SCHEMBL8292649 0.77 KCNH2 (0.46) LMNATP53MAPTLCKSMN1; SMN2
SCHEMBL8294206 0.75 KCNH2 (0.43) LMNATP53MAPTLCKSMN1; SMN2
SCHEMBL8294929 0.75 KCNH2 (0.41) LMNATP53MAPTLCKSMN1; SMN2
SCHEMBL1238558 0.74 KCNH2 (0.39) LMNATP53MAPTLCKSMN1; SMN2
SCHEMBL8292653 0.74 DYRK1A (0.41) NPC1LMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278455-B2 5- or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication JANSSEN PHARMACEUTICA N.V. (BE) 2012-10-02 US disclosed
EP-1697347-B1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION TIBOTEC PHARM LTD (IE) 2011-02-23 EP disclosed
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION JANSSEN SCIENCES IRELAND UC (IE) 2009-03-05 US disclosed
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication BONFANTI JEAN-FRANCOIS 2007-04-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070093502-A1 5- Or 6-substituted benzimidazole derivatives as inhibitors of respiratory syncytial virus replication H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SUB1, HYOU1 RAB9A 2635/4885NPC1 2491/4885LMNA 1049/4885
US-20090062278-A1 5- OR 6-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES AS INHIBITORS OF RESPIRATORY SYNCYTIAL VIRUS REPLICATION H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CYC1, SUB1 RAB9A 2354/4885NPC1 2004/4885LMNA 766/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.